NCT02556814 is a Phase 4 clinical trial of Caffeic acid tablets in Immune Thrombocytopenia, sponsored by Shandong University.

Who is sponsoring NCT02556814?

NCT02556814 is sponsored by Shandong University.

What drugs are being tested in NCT02556814?

Interventions in NCT02556814: Caffeic acid tablets, Dexamethasone, placebo.

What condition does NCT02556814 study?

NCT02556814 studies Immune Thrombocytopenia.

Is NCT02556814 still recruiting?

NCT02556814 is currently completed. Last updated 19 March 2020.

Last reviewed 2020-03-19 · How we verify

NCT02556814

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP)

Completed Phase 4 Last updated 19 March 2020

What this trial tests

Phase 4 trial testing Caffeic acid tablets in Immune Thrombocytopenia in 214 participants. Completed in 1 October 2018.

Timeline

1 September 2015

Primary endpoint
1 March 2018

1 October 2018

Quick facts

Lead sponsor	Shandong University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	214
Start date	1 September 2015
Primary completion	1 March 2018
Estimated completion	1 October 2018
Sites	1 location across China

Drugs / interventions tested

Caffeic acid tablets — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →
placebo

Conditions studied

Immune Thrombocytopenia — all drugs for Immune Thrombocytopenia →

Sponsor

Shandong University

Who can join

Adults 18 to 75, any sex, with Immune Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

sustained response to ITP treatments
Time frame: 6 months after treatment started
percentage of patients maintaining PLT count over 30\*10\^9 without bleeding

Sponsor's own description

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of caffeic acid tablets combining with high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting epigenetic regulators to overcome drug resistance in cancers.
Wang N, Ma T, Yu B, Yu B. · · 2023 · cited 213× · PMID 36797239 · DOI 10.1038/s41392-023-01341-7
Novel Biomarkers for Diagnosis and Monitoring of Immune Thrombocytopenia.
Allegra A, Cicero N, Mirabile G, Giorgianni CM, et al · · 2023 · cited 17× · PMID 36901864 · DOI 10.3390/ijms24054438
Caffeic acid tablets plus high-dose dexamethasone versus placebo plus high-dose dexamethasone in patients with newly diagnosed immune thrombocytopenia: A multicenter, double-blind, randomized, controlled, phase 2 trial.
Wang R, Liu Y, Wang R, Cao J, et al · · 2025 · cited 1× · PMID 40846660 · DOI 10.1097/cm9.0000000000003783

Verify or expand the search:

Other recruiting trials for Immune Thrombocytopenia

Currently open trials in the same condition.

NCT07104565 — Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Diso · Phase 2 · recruiting
NCT07007962 — Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed · Phase 3 · recruiting
NCT07216079 — Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan · Phase 3 · active not recruiting
NCT06776510 — A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia · Phase 1, PHASE2 · recruiting
NCT06715215 — Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia · NA · recruiting

Other Shandong University trials

Trials by the same sponsor.

NCT07288346 — Effect of Predictive Model on Double-Balloon Enteroscopy · NA · recruiting
NCT07325344 — Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study · NA · recruiting
NCT07319312 — Evaluating the Effect of Nurse-Led Stroke Transitional Care in Tanzania · recruiting
NCT07391787 — Low-acid Contrast Media for Preventing Post ERCP Pancreatitis · completed
NCT07066059 — Study on the Efficacy and Safety of Shouhui Tongbian Capsules in Protecting Intestine During the Perioperative Period · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02556814 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shandong University
Last refreshed: 19 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02556814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing